X-ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2 Symmetry

Journal of the American Chemical Society

Volumn 113, Issue 24, 1991, Pages 9382-9384

  Bone, Roger ^a   Vacca, Joseph P ^a   Anderson, Paul S ^a   Holloway, M Katharine ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIBENZYL 4 HYDROXY N,N' BIS(2 HYDROXY 1 INDANYL) 1,7 HEPTANEDIAMIDE; ENZYME INHIBITOR; L 700417; PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; X RAY ANALYSIS;

EID: 0026350729     PISSN: 00027863     EISSN: 15205126     Source Type: Journal    
DOI: 10.1021/ja00024a061     Document Type: Article

References (32)

1. Jacks, T. Nature 1988, 331, 280–283.
2. Farmerie, W. C.; Loeb, D. D.; Casavant, N. C.; Hutchison, C. A., III; Edgell, M. H.; Swanstrom, R. Science 1987, 236, 305–308.
3. Navia, M. A.; Fitzgerald, P. M. D.; McKeever, B. M.; Leu, C.-T.; Heimbach, J. C.; Herber, W. K.; Sigal, I. S.; Darke, P. L.; Springer, J. P. Nature 1989, 337, 615–620.
4. Wlodawer, A.; Miller, M.; Jasklolski, M.; Sathyanarayana, B. K.; Baldwin, E.; Weber, I. T.; Selk, L.; Clawson, L.; Schneider, J.; Kent, S. B. H. Science 1989, 245, 616–621.
5. Lapatto, R.; Blundell, T.; Hemmings, A.; Overington, J.; Wilderspin, A.; Wood, S.; Merson, J. R.; Whittle, P. J.; Danley, D. E.; Geoghegan, K. F.; Hawrylik, S. J.; Lee, S. E.; Scheld, K. G.; Hobart, P. M. Nature 1989, 342, 299–302.
6. Darke, P. L.; Leu, C.-T.; Davis, L. J.; Heimbach, J. C.; Diehl, R. E.; Hill, W. S.; Dixon, R. A. F.; Sigal, I. S. J. Biol. Chem. 1989, 264, 2307–2312.
7. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S. Proc. Natl. Acad. Sci. US.A. 1988, 85, 4686–4690.
8. McQuade, T. J.; Tomasselli, A. G.; Liu, L.; Karacostas, V.; Moss, B.; Sawyer, T. K.; Heinrikson, R. L.; Tarpley, W. R. Science 1990, 247, 454–456.
9. Umezawa, H.; Aoyagi, T.; Morishima, H.; Matsuzaki, M.; Hamada, M.; Takeuchi, T. J. Antibiot. 1970, 23, 259–262.
10. Darke, P. L.; Nutt, R. F.; Brady, S. F.; Garsky, V. M.; Ciccarone, T. M.; Leu, C.-T.; Lumma, P. K.; Freidinger, R. M.; Verber, D. F.; Sigal, I. S. Biochem. Biophys. Res. Commun. 1988, 156, 297–303.
11. Fitzgerald, P. M. D.; McKeever, B. M.; VanMiddlesworth, J. F.; Springer, J. P.; Heimbach, J. C.; Leu, C.-T.; Herber, W. K.; Dixon, R. A. F.; Darke, P. L. J. Biol. Chem. 1990, 265, 14209–14219.
12. Swain, A. L.; Miller, M. M.; Green, J.; Rich, D. H.; Schneider, J.; Kent, S. B. H.; Wlodawer, A. Proc. Natl. Acad. Sci. US.A. 1990, 87, 8805–8809.
13. Erickson, J.; Neidhart, D. J.; VanDrie, J.; Kempf, D. J.; Wang, X. C.; Norbeck, D. W.; Planner, J. J.; Rittenhouse, J. W.; Turon, M.; Widburg, N.; Kohlbrenner, W. E.; Simmer, R.; Helfrich, R.; Paul, D. A.; Knigge, M. Science 1990, 249, 527–533.
14. Lyle, T. A.; Wiscount, C. M.; Guare, J. P.; Thompson, W. J.; Anderson, P. S.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Dixon, R. A. F.; Sigal, I. S.; Huff, J. R. J. Med. Chem. 1991, 34, 1230.
15. Protease substrate nomenclature. (Schecter, I.; Berger, A. Biochem. Biophys. Res. Commun. 1967, 27, 157.)
16. N, N′-Bis(2(R)-hydroxy-l(S)-indanyl)-2(R),6(R)-bis(phenyl-methyl)-4-hydroxy-1,7-heptanediamide. Vacca, J.; Askin, D., manuscript in preparation.
17. Heimbach, J. C.; Garsky, V. M.; Michelson, S. R.; Dixon, R. A. F.; Sigal, I. S.; Darke, P. L. Biochem. Biophys. Res. Commun. 1989, 164, 955–960.
18. Vacca, J. P.; Guare, J. P.; deSolms, S. J.; Sanders, W. M.; Giuliani, E. A.; Young, S. D.; Darke, P. L.; Zugay, J. A.; Sigal, I. S., Schleif, W. A.; Quintero, J. C.; Emini, E. A.; Anderson, P. S.; Huff, J. R. J. Med. Chem. 1991, 34, 1225.
19. The HI VP complex with 2 was cocrystallized (enzyme and inhibitor in a 1:2 ratio) from NaCl by vapor diffusion as described previously for the HIVP—APS complex, and the crystals were isomorphous with the ortho-rhombic HIVP—APS crystals (P21212, a = 58.88 Å, b = 86.80 Å, c = 46.79 Å).11 Data were collected from a single crystal of enzyme-inhibitor complex using Cu Kα X-rays (λ = 1.5418) and a Siemens multiwire X-ray area detector equipped with a graphite monochromator and processed using the Xengen software (Howard, A. J.; Gilliland, G. L.; Finzel, B. C.; Poulos, T. L.; Ohlendorf, D. H.; Selemme, F. R. J. Appl. Crystallogr. 1987, 20, 383–387).
20. The data extended to 2.1-Å resolution, was 97.2% complete, had 70% of the intensities observed greater than 2σ(I), and had an overall Rmerge equal to 0.07. All measured reflections were used in refinement (Hendrickson, W. A. Methods Enzymol. 1985, 115, 252–270.
21. Smith, J. L.; Corfield, P. W. R.; Hendrickson, W. A.; Low, B. W. Acta Crystallogr. 1988, A44, 357–358).
22. (|F0| − |FC|) with structure factors (Fc) and phases (αc) calculated from the refined coordinates of the HIVP—APS complex11 minus the inhibitor.
23. Jones, T. A. J. Appl. Crystallogr. 1978, II, 268–272.
24. For simplicity, the structure of only one orientation will be discussed.
25. Coordinates have been submitted to the Brookhaven Protein Data Bank.
26. Resiudes are numbered from Al to A99 and B1 to B99.
27. Connolly, M. L. J. Appl. Crystallogr. 1983, 16, 548–558.
28. Connolly, M. L. Science 1983, 221, 709–713.
29. Using an upper estimate for the energetic gian of removing hydrophobic surfaces from solvent of 25 cal/Å2 Richards, F. M. Annu. Rev. Biophys. Bioeng. 1977, 6, 151–176.
30. Chothia, C. Nature (London) 1975, 254, 304–308. Clearly hydrophobic interactions must be offset by unfavorable consequences of binding such as the entropic cost of freezing the inhibitor conformation.
31. Miller, M.; Schneider, J.; Sathyanarayana, B. K.; Toth, M. V.; Marshall, G. R.; Clawson, L.; Selk, L.; Kent, S. B. W.; Wlodawer, A. Science 1989, 246, 1149–1152.
32. Jaskolski, M.; Tomasselli, A. G.; Sawyer, T. K.; Staples, D. G.; Heinrikson, R. L.; Schneider, J.; Kent, S. B. H.; Wlodawer, A. Biochemistry 1991, 30, 1600–1609.